Genetic
anti-CD20/CD30-CAR-T cells
anti-CD20/CD30-CAR-T cells is a genetic therapy with 2 clinical trials. Currently 1 active trials ongoing.
Total Trials
2
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
1(50%)
Phase Distribution
Ph early_phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Early Phase 1First-in-human
2(100.0%)
Highest Phase Reached
Early Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Recruiting1
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
N/A
Most Advanced
Early Phase 1
Trials by Phase
Early Phase 12 (100.0%)
Trials by Status
recruiting150%
not_yet_recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingearly_phase_1
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
NCT06532643
not_yet_recruitingearly_phase_1
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
NCT06519344
Clinical Trials (2)
Showing 2 of 2 trials
NCT06532643Early Phase 1
Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma
NCT06519344Early Phase 1
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Intravenous Anti-CD20/CD30-CAR-T Cell Infusion in Relapsed/Refractory Lymphoma Patients.
All 2 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 2